Louise Chen
Stock Analyst at Scotiabank
(2.70)
# 1,835
Out of 5,172 analysts
293
Total ratings
46.98%
Success rate
2.8%
Average return
Main Sectors:
Stocks Rated by Louise Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TEVA Teva Pharmaceutical Industries | Maintains: Sector Outperform | $35 → $40 | $28.73 | +39.23% | 5 | Jan 29, 2026 | |
| JNJ Johnson & Johnson | Maintains: Sector Outperform | $230 → $265 | $235.37 | +12.59% | 41 | Jan 22, 2026 | |
| BMY Bristol-Myers Squibb Company | Maintains: Sector Perform | $53 → $60 | $57.48 | +4.38% | 2 | Jan 9, 2026 | |
| MRK Merck & Co. | Maintains: Sector Outperform | $105 → $120 | $114.18 | +5.10% | 26 | Dec 4, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Sector Perform | $650 → $770 | $732.87 | +5.07% | 2 | Nov 24, 2025 | |
| SRPT Sarepta Therapeutics | Upgrades: Sector Outperform | $80 | $16.69 | +379.33% | 3 | Jun 6, 2025 | |
| ACRS Aclaris Therapeutics | Maintains: Sector Outperform | $15 → $9 | $3.69 | +143.90% | 6 | May 9, 2025 | |
| EWTX Edgewise Therapeutics | Downgrades: Sector Perform | $50 → $14 | $29.06 | -51.82% | 2 | Apr 3, 2025 | |
| GANX Gain Therapeutics | Initiates: Sector Outperform | $12 | $1.95 | +515.38% | 1 | Mar 7, 2025 | |
| INVA Innoviva | Initiates: Sector Outperform | $55 | $21.70 | +153.46% | 5 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Perform | $55 | $65.30 | -15.77% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $15 | $4.45 | +237.08% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $50 | $112.50 | -55.56% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $15 | $5.31 | +182.49% | 5 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $17 | $33.38 | -49.07% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $50 | $17.56 | +184.74% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $30 | $8.17 | +267.20% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $55 | $18.09 | +204.04% | 8 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $2.37 | - | 5 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $160 | $36.53 | +338.00% | 20 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $54.72 | - | 6 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $200 → $240 | $205.07 | +17.03% | 6 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $45 | $26.97 | +66.85% | 31 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $9.23 | - | 5 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $27.70 | - | 9 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $885 | $906.70 | -2.39% | 45 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $4.64 | - | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $22.98 | - | 10 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $14.36 | - | 6 | Aug 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $5.33 | - | 3 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $7.40 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $14.49 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.57 | - | 2 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.93 | - | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $65 | $4.14 | +1,470.05% | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $2.81 | +77.94% | 2 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $13.82 | +261.79% | 3 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $22.21 | +125.12% | 3 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $2.24 | +123.21% | 4 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $9 | $0.63 | +1,328.57% | 1 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $1,687,500 | $0.42 | +402,360,415.02% | 1 | Jul 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $240 → $258 | $209.27 | +23.29% | 1 | Mar 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $50 | $0.78 | +6,321.78% | 2 | Jul 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.12 | +1,685.71% | 2 | Aug 18, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $6.63 | +578.73% | 1 | Jun 22, 2017 |
Teva Pharmaceutical Industries
Jan 29, 2026
Maintains: Sector Outperform
Price Target: $35 → $40
Current: $28.73
Upside: +39.23%
Johnson & Johnson
Jan 22, 2026
Maintains: Sector Outperform
Price Target: $230 → $265
Current: $235.37
Upside: +12.59%
Bristol-Myers Squibb Company
Jan 9, 2026
Maintains: Sector Perform
Price Target: $53 → $60
Current: $57.48
Upside: +4.38%
Merck & Co.
Dec 4, 2025
Maintains: Sector Outperform
Price Target: $105 → $120
Current: $114.18
Upside: +5.10%
Regeneron Pharmaceuticals
Nov 24, 2025
Maintains: Sector Perform
Price Target: $650 → $770
Current: $732.87
Upside: +5.07%
Sarepta Therapeutics
Jun 6, 2025
Upgrades: Sector Outperform
Price Target: $80
Current: $16.69
Upside: +379.33%
Aclaris Therapeutics
May 9, 2025
Maintains: Sector Outperform
Price Target: $15 → $9
Current: $3.69
Upside: +143.90%
Edgewise Therapeutics
Apr 3, 2025
Downgrades: Sector Perform
Price Target: $50 → $14
Current: $29.06
Upside: -51.82%
Gain Therapeutics
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $12
Current: $1.95
Upside: +515.38%
Innoviva
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $55
Current: $21.70
Upside: +153.46%
Mar 7, 2025
Initiates: Sector Perform
Price Target: $55
Current: $65.30
Upside: -15.77%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $15
Current: $4.45
Upside: +237.08%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $50
Current: $112.50
Upside: -55.56%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $15
Current: $5.31
Upside: +182.49%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $17
Current: $33.38
Upside: -49.07%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $50
Current: $17.56
Upside: +184.74%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $30
Current: $8.17
Upside: +267.20%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $55
Current: $18.09
Upside: +204.04%
Nov 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.37
Upside: -
Nov 6, 2024
Reiterates: Overweight
Price Target: $160
Current: $36.53
Upside: +338.00%
Nov 6, 2024
Reiterates: Overweight
Price Target: n/a
Current: $54.72
Upside: -
Oct 31, 2024
Maintains: Overweight
Price Target: $200 → $240
Current: $205.07
Upside: +17.03%
Oct 25, 2024
Reiterates: Overweight
Price Target: $45
Current: $26.97
Upside: +66.85%
Oct 11, 2024
Reiterates: Overweight
Price Target: n/a
Current: $9.23
Upside: -
Sep 19, 2024
Reiterates: Overweight
Price Target: n/a
Current: $27.70
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $885
Current: $906.70
Upside: -2.39%
Sep 16, 2024
Reiterates: Overweight
Price Target: n/a
Current: $4.64
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $22.98
Upside: -
Aug 29, 2024
Reiterates: Overweight
Price Target: n/a
Current: $14.36
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $5.33
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $7.40
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $14.49
Upside: -
May 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.57
Upside: -
Apr 1, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.93
Upside: -
Jan 31, 2024
Reiterates: Overweight
Price Target: $65
Current: $4.14
Upside: +1,470.05%
Sep 13, 2023
Reiterates: Overweight
Price Target: $5
Current: $2.81
Upside: +77.94%
Sep 5, 2023
Reiterates: Overweight
Price Target: $50
Current: $13.82
Upside: +261.79%
Aug 22, 2023
Reiterates: Overweight
Price Target: $50
Current: $22.21
Upside: +125.12%
Aug 17, 2023
Reiterates: Neutral
Price Target: $5
Current: $2.24
Upside: +123.21%
May 12, 2023
Maintains: Overweight
Price Target: $5 → $9
Current: $0.63
Upside: +1,328.57%
Jul 7, 2021
Initiates: Overweight
Price Target: $1,687,500
Current: $0.42
Upside: +402,360,415.02%
Mar 27, 2020
Maintains: Neutral
Price Target: $240 → $258
Current: $209.27
Upside: +23.29%
Jul 19, 2018
Maintains: Overweight
Price Target: $40 → $50
Current: $0.78
Upside: +6,321.78%
Aug 18, 2017
Initiates: Overweight
Price Target: $20
Current: $1.12
Upside: +1,685.71%
Jun 22, 2017
Initiates: Overweight
Price Target: $45
Current: $6.63
Upside: +578.73%